TrialThe oncologist2025

Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.

Jean-Frédéric Blanc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.